CTKB
NASDAQ
US
Cytek Biosciences, Inc. - Common Stock
$4,53
▲ +$0,05
(+1,12%)
Vol. 436K
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$645.7M
ROE
-3,4%
Margine
-6,5%
D/E
2,18
Beta
1,31
52W
$2–$7
Consenso Wall Street
11 analisti · Apr 20263
Acquisto forte
4
Compra
4
Mantieni
0
Vendi
0
Vendita forte
63,6%
Rating Compra
Grafico dei Prezzi
Titoli simili
AZTA
Azenta Inc
$1.5B
BLFS
BioLife Solutions Inc
$1.2B
FTRE
Fortrea Holdings Inc
$1.6B
PSNL
Personalis Inc
$706.9M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7,1
$480.7M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
PACB
Pacific Biosciences of California Inc
$564.6M
LAB
Standard BioTools Inc
$492.2M
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,08
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,08 | — | — |
| Dic 2025 | $-0,02 | $-0,04 | $-0,02 |
| Set 2025 | $-0,05 | $-0,04 | +$0,01 |
| Giu 2025 | $-0,07 | $-0,04 | +$0,03 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $57.5M | $41.5M | $45.6M | $52.3M | $62.1M |
| Utile netto | — | $9.6M | -$11.4M | -$5.6M | -$5.5M | -$44.1M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -1.9% | -1.9% | -1.9% | -1.9% | -3.4% | -3.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -12.2% | -3.3% | -3.3% | -3.3% | -6.5% | -6.5% |
| Gross Margin | 52.3% | 54.4% | 54.4% | 54.4% | 53.5% | 53.5% |
| D/E Ratio | 1.65 | 1.65 | 1.65 | 1.65 | 2.18 | 2.18 |
| Current Ratio | 5.22 | 5.22 | 5.22 | 5.22 | 5.17 | 5.17 |
Rapporti chiave
ROA (TTM)
-2,6%
P/S (TTM)
3,28
P/B
2,1
EPS (TTM)
$-0,10
CF/Share
$-0,06
Crescita ricavi 3A
+16,1%
52W High
$7,30
52W Low
$2,37
$2,37
Intervallo 52 settimane
$7,30
Salute finanziaria
Flusso di cassa libero
-$1.8M
Debito netto
-$67.1M
Liquidità
$90.9M
Debito totale
$23.7M
Aggiornato al Dic 31, 2025
Як CTKB виглядає на тлі конкурентів у Life Sciences Tools & Services?
Група порівняння: Small-cap Life Sciences Tools & Services ($300M+) · 25 компаній
Оцінка CTKB vs аналоги Life Sciences Tools & Services
P/E
—
▼
0%
sotto
peer
(32,5)
vs Peer
vs Settore
Valore equo
P/S
3,3
▼
14%
sotto
peer
(3,8)
vs Peer
vs Settore
Valore equo
P/B
2,1
▼
43%
sotto
peer
(3,7)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,5%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CTKB vs аналоги Life Sciences Tools & Services
ROE
-3,4%
▼
2%
sotto
peer
(-3,3%)
vs Peer
vs Settore
In linea
Net margin
-6,5%
▲
31%
sopra
peer
(-9,4%)
vs Peer
vs Settore
Sotto media
Валова маржа
53,5%
▲
11%
sopra
peer
(48,0%)
vs Peer
vs Settore
In linea
ROA
-2,6%
▲
0%
sopra
peer
(-2,6%)
vs Peer
vs Settore
In linea
Фінансове здоровʼя CTKB vs аналоги Life Sciences Tools & Services
D/E ratio
2,2
▼
94%
sotto
peer
(36,5)
vs Peer
vs Settore
Sopra media
Поточна ліквідність
5,2
▲
53%
sopra
peer
(3,4)
vs Peer
vs Settore
Liquidità forte
Beta
1,3
▼
8%
sotto
peer
(1,4)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів CTKB
CTKB
Mediana peer
Industria
CTKB прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CTKB vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora